Werner  Kroll net worth and biography

Werner Kroll Biography and Net Worth

SVP of QuidelOrtho
Dr. Werner Kroll, Senior Vice President, Research & Development of QuidelOrtho Corporation, oversees R&D innovation for the company’s immunoassay and molecular products, leading groundbreaking developments from initial concept to manufacturability with the goal of improving human health globally.


Dr. Kroll has over three decades of industry experience, holding multiple leadership positions in research and development for major companies in the diagnostics space.


Dr. Kroll served as Senior Vice President, Research & Development of Quidel Corp. from 2014 to 2022, where he facilitated the development of countless industry-defining immunoassay and molecular products. Prior to joining Quidel, Dr. Kroll was Vice President and Global Head of Research and Innovation for Novartis Molecular Diagnostics/Codiagnostics. He has also held senior positions at Novartis Pharmaceuticals, Bayer Diagnostics, Bayer Pharmaceuticals, and AGFA. In addition, Dr. Kroll serves on the board of directors of the European Personalised Medicine Association (EPEMED).


Dr. Kroll received his Ph.D. in Physiological Chemistry from the University of Marburg.

What is Werner Kroll's net worth?

The estimated net worth of Werner Kroll is at least $875,935.08 as of February 22nd, 2021. Dr. Kroll owns 21,822 shares of QuidelOrtho stock worth more than $875,935 as of November 23rd. This net worth estimate does not reflect any other assets that Dr. Kroll may own. Additionally, Dr. Kroll receives a salary of $1,030,000.00 as SVP at QuidelOrtho. Learn More about Werner Kroll's net worth.

How old is Werner Kroll?

Dr. Kroll is currently 67 years old. There are 8 older executives and no younger executives at QuidelOrtho. The oldest executive at QuidelOrtho is Mr. William J. Ferenczy, Point of Care Business Unit Leader, who is 68 years old. Learn More on Werner Kroll's age.

What is Werner Kroll's salary?

As the SVP of QuidelOrtho Co., Dr. Kroll earns $1,030,000.00 per year. The highest earning executive at QuidelOrtho is Ms. Michelle A. Hodges J.D., Senior VP, General Counsel & Corporate Secretary, who commands a salary of $1,800,000.00 per year. Learn More on Werner Kroll's salary.

How do I contact Werner Kroll?

The corporate mailing address for Dr. Kroll and other QuidelOrtho executives is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. QuidelOrtho can also be reached via phone at (800) 874-1517 and via email at [email protected]. Learn More on Werner Kroll's contact information.

Has Werner Kroll been buying or selling shares of QuidelOrtho?

Werner Kroll has not been actively trading shares of QuidelOrtho during the last ninety days. Most recently, Werner Kroll sold 5,283 shares of the business's stock in a transaction on Wednesday, February 24th. The shares were sold at an average price of $173.71, for a transaction totalling $917,709.93. Following the completion of the sale, the senior vice president now directly owns 21,822 shares of the company's stock, valued at $3,790,699.62. Learn More on Werner Kroll's trading history.

Who are QuidelOrtho's active insiders?

QuidelOrtho's insider roster includes Michael Abney, Jr. (SVP), Douglas Bryant (CEO), Joseph Busky (CFO), William Ferenczy (SVP), Werner Kroll (SVP), Edward Michael (Director), Mary Polan (Director), Charles Slacik (Director), Randall Steward (CFO), and Matthew Strobeck (Director). Learn More on QuidelOrtho's active insiders.

Are insiders buying or selling shares of QuidelOrtho?

During the last year, QuidelOrtho insiders bought shares 1 times. They purchased a total of 2,150 shares worth more than $99,652.50. During the last year, insiders at the sold shares 25 times. They sold a total of 10,521,742 shares worth more than $374,367,521.97. The most recent insider tranaction occured on November, 21st when Major Shareholder Carlyle Group Inc. sold 8,260,183 shares worth more than $291,667,061.73. Insiders at QuidelOrtho own 1.0% of the company. Learn More about insider trades at QuidelOrtho.

Information on this page was last updated on 11/21/2024.

Werner Kroll Insider Trading History at QuidelOrtho

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/24/2021Sell5,283$173.71$917,709.9321,822View SEC Filing Icon  
2/22/2021Sell12,784$164.11$2,097,982.2421,822View SEC Filing Icon  
8/3/2020Sell2,072$287.48$595,658.564,599View SEC Filing Icon  
5/22/2020Sell68,152$174.44$11,888,434.88View SEC Filing Icon  
12/3/2019Sell22,951$70.93$1,627,914.43
12/8/2017Sell16,358$40.44$661,517.5210,818View SEC Filing Icon  
11/6/2017Sell7,565$39.50$298,817.5010,261View SEC Filing Icon  
See Full Table

Werner Kroll Buying and Selling Activity at QuidelOrtho

This chart shows Werner Kroll's buying and selling at QuidelOrtho by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

QuidelOrtho Company Overview

QuidelOrtho logo
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $40.14
Low: $37.49
High: $40.81

50 Day Range

MA: $41.38
Low: $36.18
High: $46.35

2 Week Range

Now: $40.14
Low: $29.74
High: $75.86

Volume

4,300,219 shs

Average Volume

921,692 shs

Market Capitalization

$2.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.12